CN112294915A - 一种治疗肺气肿的药物组合物及其制备方法 - Google Patents
一种治疗肺气肿的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN112294915A CN112294915A CN202011141542.2A CN202011141542A CN112294915A CN 112294915 A CN112294915 A CN 112294915A CN 202011141542 A CN202011141542 A CN 202011141542A CN 112294915 A CN112294915 A CN 112294915A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treating emphysema
- preparation
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010014561 Emphysema Diseases 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000004072 lung Anatomy 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 claims abstract description 15
- 241000764065 Persicaria capitata Species 0.000 claims abstract description 15
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 15
- 208000026435 phlegm Diseases 0.000 claims abstract description 15
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 14
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 12
- 230000008961 swelling Effects 0.000 claims abstract description 12
- 241000219094 Vitaceae Species 0.000 claims abstract description 9
- 235000021021 grapes Nutrition 0.000 claims abstract description 9
- 241001313857 Bletilla striata Species 0.000 claims abstract description 7
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 7
- 244000294611 Punica granatum Species 0.000 claims abstract 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 239000000463 material Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 7
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 7
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 7
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 241001313855 Bletilla Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000021551 crystal sugar Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000857 drug effect Effects 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000007812 deficiency Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 14
- 241000219991 Lythraceae Species 0.000 description 12
- 206010042674 Swelling Diseases 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 241000219095 Vitis Species 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000723347 Cinnamomum Species 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000003123 bronchiole Anatomy 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000008648 bailing capsule Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000026636 chronic pulmonary heart disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- AFOLOMGWVXKIQL-UHFFFAOYSA-O petunidin Chemical compound OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 AFOLOMGWVXKIQL-UHFFFAOYSA-O 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗肺气肿的药物组合物及其制备方法。所述的治疗肺气肿的中药组合物由以下重量份的原材料制备而成:葡萄40~80份,石灰华10~30份,红花20~60份,红参10~20份,五味子10~20份,甘草1~5份,头花蓼15~45份,石榴10~30份,冰糖30~60份,桂皮5~15份,以及选自白及5~15份,厚朴5~15份中的至少一种。本发明基于中医药理论,结合现代提取分离技术,配方简单,各原料药协同作用起到消肿解毒,补肺益气、化痰平喘的效果,标本兼治,见效快,服用方便,用药量低。
Description
技术领域
本发明涉及一种药物组合物,具体涉及一种治疗肺气肿的药物组合物。
背景技术
肺气肿是呼吸系统的常见病、多发病,但却不是临床上一类独立的疾病,而是肺脏终末支气管远端的部位,包括呼吸细支气管、肺泡管、肺泡囊和肺泡的膨胀与过度充气,导致肺组织弹力减退和容积增大的总称。它的发病缓过程慢,病程较长,可导致呼吸衰竭和心功能衰竭,威胁患者生命。中老年人为该病的多发群体,很多人发展到晚期因严重喘憋而活动受限,生活质量极差。肺气肿还跟严重威胁生命的慢性肺源性心脏病、肺纤维化都具有密切关系。
肺气肿的主要临床表现为:气急、气短、咳嗽、咯痰、呼吸困难、胸闷、哮鸣音等;在自身抵抗力下降、劳累、吸烟、吸入各种粉尘、大气污染、气候骤变等因素的刺激下还会加重。因此,在我国北方地区发病率、病死率均较高。目前,国内治疗肺气肿主要采用肺减容术、呼吸机正压通气治疗、药物治疗、康复训练等。保守治疗以改善患者的呼吸功能、预防气道感染、控制并发症为主,虽有一定作用,但不能阻止病情的发展,尤其是对晚期患者的治疗极为有限。目前认为有效的手术方法只有肺移植术和肺减容术,但因适应证窄、并发症多、供肺缺乏等,不能广泛开展。
肺气肿病程较长,治疗周期较长,本虚标实,病及多脏,变证较多,尤其是部分老年患者,因正虚反复感邪,致病情进行性加重。中医药对本病病因、病机的探讨及治疗研究有了较大的进展:分析病机强调辨析虚实,观察病程重视分期,临床治疗注重辨证施治,用药注重传统剂型的改革,判断预后注重肺功能、血气分析等客观指标的变化,治疗前景乐观。针对市场现状,本发明基于中医药理论,结合现代提取工艺,研制成标准化可用于预防、控制及治疗肺气肿的中药组合制剂。
发明内容
本发明的目的是解决现有技术的不足,提供一种配比科学合理,疗效确切,临床使用安全,不良反应低、服用方便的药物组合物及其制备方法。
为了实现以上目的,本发明采取的技术方案为,
治疗肺气肿的药物组合物包括以下原材料:石灰华,红花,葡萄,红参,五味子,甘草,头花蓼,石榴,冰糖,桂皮,以及选自白及,厚朴的至少一种。
进一步地,所述的药物组合物,由以下重量份的原料制得:石灰华10~30份,红花20~60份,葡萄40~80份,红参10~20份,五味子10~20份,甘草1~5份,头花蓼15~45份,石榴10~30份,冰糖30~60份,桂皮5~15份,以及选自白及5~15份,厚朴5~ 15份中的至少一种。
由以下重量份的原料制得:石灰华10~30份,红花20~60份,葡萄40~80份,红参10~20份,五味子10~20份,甘草1~5份,头花蓼15~45份,石榴10~30份,冰糖30~60份,桂皮5~15份,白及5~15份,厚朴5~15份。
进一步地,所述的药物组合物,由以下重量份的原料制得:石灰华10~20份,红花30~40份,葡萄50~70份,红参10~15份,五味子10~15份,甘草1~3份,头花蓼25~40份,石榴15~25份,冰糖30~60份,桂皮5~10份,白及5~10份,厚朴5~10份。
进一步地,所述一种治疗肺气肿的药物组合物的制备方法,其特征在于,取处方量的各药材粉碎、过筛,得药材组合物。
进一步地,所述一种治疗肺气肿的中药组合物及其制备方法,其特征在于,所述制备方法包括以下步骤,
(1)取处方量的各药材,加适量溶剂浸渍1~5h,所述溶剂为水、乙醇或水和乙醇的混合物,所述溶剂用量为药材总量的1~10倍,再进行渗漉,收集渗漉液,过滤;
(2)将步骤(1)中过滤所得滤渣进行煎煮1~2次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量不超过10%的组合物浸膏干品。
进一步,所述一种治疗肺气肿的中药组合物及其制备方法,其特征在于,所述制备方法包括以下步骤,
(1)药材前处理:将处方量的甘草、桂皮、头花蓼,白及,五味子,厚朴6味药材进行粉碎,过80目筛,得药材混合物A;将处方量的红参、红花、石灰华,葡萄、石榴、冰糖粉碎,过筛,得到药材混合物B;
(2)药材成分提取:取药材混合物A,加适量溶剂浸渍1~5h,所述溶剂为水、乙醇或水和乙醇的混合物,所述溶剂用量为药材总量的1~10倍,再进行渗漉,收集渗漉液,过滤;滤渣再煎煮1~2次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量不超过10%的组合物浸膏干品;
(3)混合:将浸膏干品,粉碎,与药材混合物A和药材混合物B 充分混合;
进一步地,所述的药物组合物,可适当地添加合适的药学上可接受的辅料,可生产任何常规剂型,考虑到患者的接受度和药效,所述制剂优选为口服剂型,可选择颗粒剂、散剂、胶囊剂或汤剂。
进一步地,所述的治疗肺气肿的药物组合物胶囊剂,所采用的胶囊壳是指以植物淀粉为原料,以甘油和水为辅料制成的植物淀粉胶囊。
本发明提供的是治疗肺气肿的中药组合物,根据中医药理论辩证论治筛选组方,方中,
石灰华:又名孔石,属于石灰石和大理石。一般是奶油色或淡红色,由温泉的方解石沉积而成。生于海拔2000~4000m的石灰山洞、河流、泉等地。分布于西藏林芝、直贡、岗递斯,以及上区阿里等高原各地。微甘,寒。清热补肺,用于各种肺热病。《四部医典》载:“治各类肺病,消外伤引起的炎症。”《甘露本草明镜》载:“治肺炎及各类肺病,利于疮伤、热症散于骨骼及温疫症。”
红花:辛,温。《本草经解》:入足厥阴肝经,手太阴肺经。入心、肝经。活血通经,散瘀止痛,有助于治经闭、痛经、恶露不行、胸痹心痛、瘀滞腹痛、胸胁刺痛、跌打损伤、疮疡肿痛疗效。有活血化瘀,散湿去肿的功效。《医林改错》载:“活血行气,祛瘀通络,通痹止痛,主治气血痹阻经络所致的肩痛,臂痛,腰痛,腿痛,或周身疼痛,经久不愈。”
葡萄:甘酸,平。入肺、脾、肾经。补气血,强筋骨,利小便。治气血虚弱,肺虚咳嗽,心悸盗汗,风湿痹病,淋病,浮肿。果:解表透疹,利尿,安胎。用于麻疹不透,小便不利,胎动不安。根、藤:祛风湿,利尿。用于风湿骨痛,水肿;外用治骨折。葡萄含葡萄糖、果糖,少量蔗糖、木糖,酒石酸、草酸、柠檬酸、苹果酸。又含各种花色素的单葡萄糖甙和双葡萄糖甙。叶、茎有收敛作用。葡萄皮含矢车菊素、芍药素、飞燕草素、矮牵牛素、锦葵花素、锦葵花素-3-β- 葡萄糖甙。种子含油量9.58%。又含焦性儿茶酚、没食子儿茶精、没食子酸盐等。《本草再新》载:“暖胃健脾,治肺虚寒嗽,贩血积疽瘤。”
红参:大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。《药性论》载:主五脏气不足,五劳七伤,虚损瘦弱,吐逆不下食,止霍乱烦闷呕哕,补五脏六腑,保中守神。“消胸中痰,主肺痿吐脓及痫疾,冷气逆上,伤寒不下食,患人虚而多梦纷纭,加而用之。”
五味子:敛肺,滋肾,生津,收汗,涩精。治肺虚喘咳,口干作渴,自汗,盗汗,劳伤羸瘦,梦遗滑精,久泻久痢。主益气,咳逆上气,养五脏,除热,生阴中肌,消水肿。
甘草:味甘,性平。归心、肺、脾、胃经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。甘草:具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药之功效。常用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
头花蓼:酸,寒。清热凉血,利尿。用于泌尿系感染,痢疾,腹泻,血尿;外用治尿布疹,黄水疮。该种全草入药,治尿道感染、肾盂肾炎。
石榴:性味甘、酸涩、温,具有杀虫、收敛、涩肠、止痢等功效。石榴果实营养丰富,维生素C含量比苹果、梨要高出一二倍。石榴叶:收敛止泻;角毒杀虫。主泄泻;痘风疮;癞疮;跌打损伤。
冰糖:味甘,性平,无毒。入脾、肺二经。具有润肺、止咳、清痰、和去火的作用。也是泡制药酒、炖煮补品的辅料。冰糖具有补中益气、和胃润肺、止咳化痰、祛烦消渴、清热降浊、养阴生津、止汗解毒等功能,可用于治疗中气不足、肺热咳嗽、咯痰带血、阴虚久咳、口燥咽干、咽喉肿痛、小儿盗汗、风火牙痛等病症。
桂皮:味辛、甘,性温。归脾、胃、肝、肾经。温中散寒,理气止痛。用于脘腹冷痛,呕吐泄泻,腰膝酸冷,寒疝腹痛,寒湿痹痛,瘀滞痛经,血痢,肠风,跌打肿痛,创伤出血等。
白及:苦、甘、涩,微寒。归肺、肝、胃经。收敛止血,消肿生肌。用于咯血,吐血,外伤出血,疮疡肿毒,皮肤皲裂。
厚朴:味苦、辛,性温。归脾、胃、肺、大肠经。燥湿消痰,下气除满。用于湿滞伤中,脘痞吐泻,食积气滞,腹胀便秘,痰饮喘咳。树皮、根皮、花、种子及芽皆可入药,以树皮为主,为中药,有化湿导滞、行气平喘、化食消痰、驱风镇痛之效;种子有明目益气功效,芽作妇科药用。
有益效果:本发明根据中医药理论和呼吸系统疾病的发病特点,采用辨证论治的理论进行中药组方筛选,石灰华清热补肺,清热消炎,红花活血化瘀、消湿去肿,共除治病之因,合而为君药;红参大补元气、固脱生津,冰糖润肺、止咳、清痰,葡萄暖胃健脾,治肺虚寒嗽,五味子敛肺,滋肾,生津,咳逆上气,养五脏,四药相配,养肺益气,调和气血共为臣药;白及消肿生肌、疮疡肿毒,桂皮温中散寒,理气止痛,厚朴行气平喘,化食消痰,头花蓼清热,石榴杀虫、收敛,五药合用,消炎去肿,平喘化痰同为佐药;甘草补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药为使药。选取的12种天然中药科学配伍,配方简单,各原料药协同作用起到消肿解毒,补肺益气、化痰平喘的效果,标本兼治,见效快,服用方便,用药量低,可用于肺气肿的预防、控制及治疗。
具体实施方式
以下通过数个实施例进一步说明本发明。应当理解,所列举的所有实施例均为帮助本领域技术人员理解和实施本发明,并非任何形式的对本发明的任何限制。一切在本发明基础上进行的简单改进和调整,以及将其中的原料进行等同或等效的替换,而未能产生新的实质性特点和显著进步的,均应在本发明的保护范围之内。
实施例1
(1)粉碎:称取石灰华10份、红花30份、葡萄40份、红参10 份、五味子20份、甘草1份、头花蓼15份、石榴10份、桂皮5份、冰糖30份、白及5份,粉碎,过80目筛。
(2)将上述原料粉中加入硬脂酸镁4份,微晶纤维素1份,聚乙二醇3份,低取代羟丙纤维素5份与适量淀粉混合均匀,加入95%酒精制颗粒,过20目筛,60℃干燥(水分3.6%)装袋制成颗粒剂。
实施例2
(1)取葡萄60份、甘草5份、桂皮15份、头花蓼45份、五味子20份、石灰华10份、红花30份、冰糖30份、石榴30份、红参 20份,加适量溶剂浸渍3h,所述溶剂为60%乙醇水溶液,所述溶剂用量为药材总量的5倍,再进行渗漉,收集渗漉液,过滤。
(2)将步骤(1)中过滤所得滤渣进行煎煮1次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量不超过10%的组合物浸膏干品,粉碎。
(3)总混:将步骤(1)和步骤(2)中搅拌混合后,加入步骤(1) 中的红花粉末和石灰华粉末,充分混合,收膏,干燥,粉碎,过100 目筛。
(4)将上述原料粉中加入硬脂酸镁6份,微晶纤维素3份,聚乙二醇5份,低取代羟丙纤维素5份与适量淀粉混合均匀,加入95%酒精制颗粒,过20目筛,60℃干燥(水分2.8%),压片制成片剂。
实施例3
(1)药材前处理:称取甘草5份、桂皮12份、头花蓼20份,白及5份,五味子10份,厚朴10份,粉碎,过80目筛,得药材混合物A;称取红参10份、红花30份、石灰华10份、冰糖35份、葡萄 40份、石榴10份,粉碎,过80目筛,得到药材混合物B。
(2)药材成分提取:取药材混合物A,加5倍量60%乙醇水溶液浸渍5h,再进行渗漉,收集渗漉液,过滤;滤渣再煎煮2次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量5.4%的组合物浸膏干品。
(3)混合:将浸膏干品粉碎,与药材混合物充分混合。
(4)将上述原料粉中加入硬脂酸镁5份,微晶纤维素2份,聚乙二醇4份,低取代羟丙纤维素6份与适量淀粉混合均匀,加入95%酒精制颗粒,过20目筛,60℃干燥(水分3.1%)装入羟丙基淀粉空心胶囊制成胶囊剂。
实施例4
(1)药材前处理:称取甘草3份、桂皮10份、头花蓼30份,白及10份,五味子15份,厚朴10份,粉碎,过80目筛,得药材混合物A;称取红参15份、红花40份、石灰华20份、冰糖35份、葡萄 60份、石榴20份,粉碎,过80目筛,得到药材混合物B。
(2)药材成分提取:取药材混合物A,加4倍量70%乙醇水溶液浸渍3h,再进行渗漉,收集渗漉液,过滤;滤渣再煎煮1次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量5.8%的组合物浸膏干品。
(3)混合:将浸膏干品,粉碎,与药材混合物充分混合。
(4)将上述原料粉中加入硬脂酸镁5份,微晶纤维素2份,聚乙二醇4份,低取代羟丙纤维素6份与适量淀粉混合均匀,加入95%酒精制颗粒,过20目筛,60℃干燥(水分2.9%)装入羟丙基淀粉空心胶囊制成胶囊剂。
实施例5动物实验
取体重相近的健康小鼠共100只雌雄各半,分为5组,每组20 只,雌雄各半,置于染毒箱内(箱体大小90cm×60cm×60cm,箱顶留有1.6cm直径的通气孔)被动吸烟,箱内放置钠石灰吸收二氧化碳,无水氯化钙吸收水蒸气,5支/次,持续30min次,2次/d,两次吸烟间隔4h,吸烟之外的时间正常,染毒60d后,第1组设为空白组喂等量的食物,第2~4组分别喂养实施例1~3制备的药物组合物进行治疗(10mg/kg,一日三次),第5组为阳性对照组,喂养百令胶囊进行治疗,观察给药后即刻至30d内小鼠的总体健康水平、体重变化,每天至少观察两次,30d后检测完肺功能,即对所有实验小鼠进行摘眼球放血处死,开胸游离心肺,气管插管并固定气管插管后,完整取出心肺组织进行组织病理学检查。
结果:实验过程中,空白组和实验组无一只小鼠死亡,均进入结果分析。实验过程中,给药第3、7、10、14、21和30天时称体重与空白组(如表1所示):空白组小鼠体弱瘦小,且体重一直呈下降趋势,实施例1~3小鼠体重逐渐增加至恢复正常,阳性对照组小鼠体重逐渐增加但恢复幅度缓慢;30天后解剖小鼠,小鼠肺内细支气管、终末细支气管的白细胞总数、巨噬细胞、中性粒细胞、淋巴细胞显著低于空白对照及阳性药物对照组(如表2所示),表明本发明药物组合物可有效消除肺气肿病症炎症及浮肿。肺组织病理切片HE染色及肺组织羟脯氨酸含量(如表3所示)结果表明:实施例1~3较空白对照组及阳性对照组肺内呼吸性细支气管、肺管泡囊及肺泡明显缩小,肺泡间隔、肺泡壁无断裂,无炎症细胞浸润,胶原在气道壁沉积显著减少,炎症消失,肺组织羟脯氨酸含量显著降低,无明显肺组织纤维化表征。
表1给药30天小鼠体重变化对比情况
与空白对照组相比,**P<0.01,*P<0.05。
表3各组小鼠肺部炎症积分、胶原组织沉积厚度及羟脯氨酸含量
项目 | 空白组 | 实施例1 | 实施例2 | 实施例3 | 阳性参照组 |
炎症积分 | 1.47±0.04 | 0.23±0.04* | 0.25±0.03* | 0.23±0.04* | 0.46±0.07 |
胶原(μm<sup>2</sup>/μm) | 5.71±0.09 | 1.77±0.11** | 1.66±0.10** | 1.70±0.13** | 1.89±0.24** |
羟脯氨酸(μg/g) | 549±34.21 | 401±12.15** | 414±21.89** | 409±30.49** | 427±12.51** |
上述参照实施例对一种治疗肺气肿的药物组合物及其制备方法进行的详细描述,是说明性的而不是限定性的,可按照所限定范围列举出若干个实施例,因此在不脱离本发明总体构思下的变化和修改,应属本发明的保护范围之内。
Claims (8)
1.一种治疗肺气肿的药物组合物,其特征在于其包括以下原材料:
石灰华,红花,葡萄,红参,五味子,甘草,头花蓼,桂皮,石榴,冰糖,以及选自白及,厚朴中的至少一种。
2.根据权利要求1中所述的药物组合物,其特征在于由以下重量份的原料制得:葡萄40~80份,石灰华10~30份,红花20~60份,红参10~20份,五味子10~20份,甘草1~5份,头花蓼15~45份,石榴10~30份,冰糖30~60份,桂皮5~15份,以及选自白及5~15份,厚朴5~15份中的至少一种。
3.根据权利要求1中所述一种治疗肺气肿的药物组合物的制备方法,其特征在于,取处方量的各药材粉碎、过筛,得药物组合物。
4.根据权利要求1中所述一种治疗肺气肿的中药组合物及其制备方法,其特征在于,所述制备方法包括以下步骤:
(1)取处方量的各药材,加适量溶剂浸渍1~5h,所述溶剂为水、乙醇或水和乙醇的混合物,所述溶剂用量为药材总量的1~10倍,再进行渗漉,收集渗漉液,过滤;
(2)将步骤(1)中过滤所得滤渣进行煎煮1~2次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量不超过10%的组合物浸膏干品。
5.根据权利要求1中所述一种治疗肺气肿的中药组合物及其制备方法,其特征在于,所述制备方法包括以下步骤:
(1)药材前处理:将处方量的甘草、桂皮、头花蓼,白及,五味子,厚朴、葡萄、石榴6味药材进行粉碎,过筛,得药材混合物A;将处方量的红参、红花、石灰华、冰糖,粉碎,过筛,得到药材混合物B;
(2)药材成分提取:取药材混合物A,加适量溶剂浸渍1~5h,所述溶剂为水、乙醇或水和乙醇的混合物,所述溶剂用量为药材总量的1~10倍,再进行渗漉,收集渗漉液,过滤;滤渣再煎煮1~2次,过滤,合并滤液,减压回收乙醇,将滤液真空减压浓缩至稠膏状,干燥,得水分含量不超过10%的组合物浸膏干品;
(3)混合:将浸膏干品粉碎,与药材混合物A和药材混合物B充分混合。
6.根据权利要求1所述的药物组合物,可适当地添加合适的药学上可接受的辅料,可生产任何常规剂型,考虑到患者的接受度和药效,所述制剂为口服剂型,可选择颗粒剂、散剂、胶囊剂或汤剂。
7.根据权利要求6所述的胶囊剂,其特征在于,胶囊剂所采用的胶囊壳是指以植物淀粉为原料,以甘油和水为辅料制成的植物淀粉胶囊。
8.根据权利要求1~7所述的药物组合物,其特征在于,本药物组合具有消肿解毒,补肺益气、化痰平喘的功效,可用于肺气肿的预防、控制及治疗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011141542.2A CN112294915B (zh) | 2020-10-22 | 2020-10-22 | 一种治疗肺气肿的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011141542.2A CN112294915B (zh) | 2020-10-22 | 2020-10-22 | 一种治疗肺气肿的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112294915A true CN112294915A (zh) | 2021-02-02 |
CN112294915B CN112294915B (zh) | 2022-04-15 |
Family
ID=74326752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011141542.2A Active CN112294915B (zh) | 2020-10-22 | 2020-10-22 | 一种治疗肺气肿的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112294915B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793840A (zh) * | 2012-08-24 | 2012-11-28 | 内蒙古鄂尔多斯市蒙医研究所 | 一种治疗支气管炎的蒙药复方制剂及其制备方法 |
CN103710221A (zh) * | 2012-10-08 | 2014-04-09 | 江月锋 | 一种肺气肿川桂枝保健酒 |
CN103830696A (zh) * | 2014-02-16 | 2014-06-04 | 王树军 | 一种用于治疗肺气肿的中药 |
-
2020
- 2020-10-22 CN CN202011141542.2A patent/CN112294915B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793840A (zh) * | 2012-08-24 | 2012-11-28 | 内蒙古鄂尔多斯市蒙医研究所 | 一种治疗支气管炎的蒙药复方制剂及其制备方法 |
CN103710221A (zh) * | 2012-10-08 | 2014-04-09 | 江月锋 | 一种肺气肿川桂枝保健酒 |
CN103830696A (zh) * | 2014-02-16 | 2014-06-04 | 王树军 | 一种用于治疗肺气肿的中药 |
Non-Patent Citations (2)
Title |
---|
揭金阶等: "《临床中成药物学》", 31 October 2004, 湖北科学技术出版社 * |
石剑华: "《传统蒙兽医成验方选编》", 3 April 2016, 内蒙古科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN112294915B (zh) | 2022-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
CN104001045A (zh) | 一种用于治疗犬肺炎的药物及其制备方法 | |
CN112294915B (zh) | 一种治疗肺气肿的药物组合物及其制备方法 | |
CN102406905B (zh) | 一种预防或治疗慢性萎缩性胃炎的药物组合物及应用 | |
CN101028451B (zh) | 一种治疗三叉神经痛的中成药 | |
CN103417911A (zh) | 化疗辅助用中药组合物 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN105688171B (zh) | 一种雏鸡用饲料添加剂及其制备方法 | |
CN103550351B (zh) | 治疗偏头疼的中药组合物及其制备方法 | |
CN106692821A (zh) | 一种治疗神经外科术后头痛的中药制剂 | |
CN104667247A (zh) | 一种治疗咳嗽的中药组合物及其制备方法 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105267815A (zh) | 一种治疗小儿肺肾两虚型哮喘的喷雾剂及其制备方法 | |
CN104491537A (zh) | 一种治疗风湿性心脏病的中药组合物 | |
CN104906439A (zh) | 一种用于治疗慢性呼吸衰竭的药物 | |
CN104189199A (zh) | 一种治疗尿路感染的药物组合物及其制备方法 | |
CN104107357A (zh) | 一种止咳化痰颗粒及其制备方法 | |
CN112791125A (zh) | 一种治疗坐骨神经痛的中药制剂及其制备方法 | |
CN114533847A (zh) | 一种用于辅助治疗肺病的中药穴位敷贴剂 | |
CN114588226A (zh) | 一种治疗骨折的中药组合物及其制备方法 | |
CN115317580A (zh) | 一种清除幽门螺杆菌的中药制剂及其制备方法 | |
CN107753909A (zh) | 一种治疗小儿咳嗽的内服药物及制备方法 | |
CN102772640A (zh) | 一种治疗哮喘的药物及其制备方法 | |
CN107898973A (zh) | 一种治疗鼻炎的贴剂及其制备方法 | |
CN108339018A (zh) | 一种治疗支气管炎的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |